PMID- 32904666 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220416 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 13 DP - 2020 TI - Exosomal-lncRNA DLEU1 Accelerates the Proliferation, Migration, and Invasion of Endometrial Carcinoma Cells by Regulating microRNA-E2F3. PG - 8651-8663 LID - 10.2147/OTT.S262661 [doi] AB - PURPOSE: Long non-coding RNAs (lncRNAs) may act as oncogenes in several cancers, including endometrial carcinoma (EC). The purpose of the current study is to investigate the regulatory mechanism of exosomal-lncRNA deleted in lymphocytic leukemia1 (DLEU1) on EC. METHODS: The expression levels of lncRNA DLEU1, microRNA-381-3p and E2F Transcription Factor 3 (E2F3) in EC tissues or cells were detected using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). We then analysed the proliferation, migration, and invasion of EC cells by performing the MTT assay, wound healing assay, and transwell invasion assay, respectively. Identification of exosomes was detected using Western blot assay. The uptake of exosomes was detected by a confocal microscope. The effects of exosomes on EC cells were investigated by construction of cell co-culture system. The interactions among DLEU1, miR-381-3p and E2F3 were confirmed using the dual-luciferase reporter (DLR) assay. RESULTS: LncRNA DLEU1 expression was highly up-regulated in EC tissues and cells. Knockdown of DLEU1 inhibited the proliferation, migration, and invasion of EC cells. Exosomes could be uptaken by the ambient EC cells. MiR-381-3p was a target of DLEU1 and was negatively modulated by DLEU1. Overexpression of miR-381-3p suppressed the proliferation, migration, and invasion of EC cells. Additionally, E2F3 was the target gene of miR-381-3p and was negatively modulated by miR-381-3p. Upregulation of miR-381-3p and down-regulation of E2F3 reversed the promoting effect of exosomal DLEU1 on EC cells. CONCLUSION: Exosomal DLEU1 accelerates the development of EC by regulating the miR-381-3p/E2F3 axis, thus DLEU1 may act as a possible therapeutic target for treating EC. CI - (c) 2020 Jia et al. FAU - Jia, Jianjun AU - Jia J AD - Department of Obstetrics and Gynecology, The First Affiliated Hospital, Jinan University, Guangzhou City, Guangdong Province 510632, People's Republic of China. FAU - Guo, Suiqun AU - Guo S AD - Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Southern Medical University, Guangzhou City, Guangdong Province, People's Republic of China. FAU - Zhang, Dong AU - Zhang D AD - Department of Obstetrics and Gynecology, The First Affiliated Hospital, Jinan University, Guangzhou City, Guangdong Province 510632, People's Republic of China. FAU - Tian, Xiaohui AU - Tian X AD - Department of Obstetrics and Gynecology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen City, Guangdong Province, People's Republic of China. FAU - Xie, Xingmei AU - Xie X AD - Department of Obstetrics and Gynecology, The First Affiliated Hospital, Jinan University, Guangzhou City, Guangdong Province 510632, People's Republic of China. LA - eng PT - Journal Article DEP - 20200825 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC7457553 OTO - NOTNLM OT - E2F3 OT - endometrial carcinoma OT - exosomes OT - lncRNA DLEU1 OT - miR-381-3p COIS- The authors report no conflicts of interest for this work. EDAT- 2020/09/10 06:00 MHDA- 2020/09/10 06:01 PMCR- 2020/08/25 CRDT- 2020/09/09 18:06 PHST- 2020/05/13 00:00 [received] PHST- 2020/07/24 00:00 [accepted] PHST- 2020/09/09 18:06 [entrez] PHST- 2020/09/10 06:00 [pubmed] PHST- 2020/09/10 06:01 [medline] PHST- 2020/08/25 00:00 [pmc-release] AID - 262661 [pii] AID - 10.2147/OTT.S262661 [doi] PST - epublish SO - Onco Targets Ther. 2020 Aug 25;13:8651-8663. doi: 10.2147/OTT.S262661. eCollection 2020.